BioKier is a technology company.
BioKier has raised $2.0M across 1 funding round.
BioKier has raised $2.0M in total across 1 funding round.
BioKier is a clinical-stage biotechnology company developing oral products for managing lipids and glucose, primarily targeting type 2 diabetes, metabolic syndrome, obesity, and related cardiometabolic disorders.[1][2][4] Its lead candidate, BKR-017, delivers nutrients like butyrate or L-glutamine to the colon to restore gut hormone secretion, mimicking bariatric surgery's effects on diabetes resolution and cardiometabolic health.[3][4][6] The company has raised $2.48M in funding, completed preclinical and early clinical trials showing improved glucose and lipid regulation, and pursues commercialization via the 505(b)(2) NDA pathway or as a medical food using GRAS ingredients.[1][2][5] BioKier serves patients with insulin resistance and cardiometabolic disease, addressing limitations of existing therapies like statins and injectables, which often wane in efficacy or cause side effects.[4][5]
BioKier, based in Chapel Hill, North Carolina, emerged from research identifying impaired gut hormone secretion in diabetes and cardiometabolic disease (CMD), where nutrients fail to reach the colon's L-cells due to upper gut absorption.[3][4] The company developed a colon-targeting formulation for safe nutrient delivery—initially L-glutamine, a potent natural gut hormone secretagogue abundant in food, later advancing to butyrate in BKR-017.[3][4] Proof-of-concept came from acute studies via catheter delivery in diabetic animals and humans, restoring glucose-induced gut hormone responses, followed by oral demonstrations in animal models and clinical proof in patients.[3][4] Funded partly through SBIR grants, BioKier has evolved from early-stage medical food development to clinical trials, with 17 patents filed on diabetes-related innovations like diketones and fluoroarenes.[1][3]
BioKier rides the wave of gut microbiome and hormone modulation trends in cardiometabolic disease, where bariatric surgery's success highlights the colon's role in L-cell stimulation for GLP-1-like effects, amid rising demand for oral alternatives to injectables like GLP-1 agonists.[2][3][5] Timing aligns with a booming diabetes market driven by type 2 prevalence, technological advances in continuous glucose monitoring, and needs for convenient, affordable therapies amid regulatory pushes for personalized metabolic treatments.[1] Market forces favor it: large, growing segments for diabetes ($ billions), obesity, and NASH; gaps in statin tolerance (25% intolerance) and waning drug efficacy; plus insurance pressures for non-injectable options.[5] BioKier influences the ecosystem by pioneering nutrient-based, surgery-mimicking orals, potentially lowering barriers to advanced care and spurring colon-delivery innovations in biotech.[2][3]
BioKier could advance BKR-017 to Phase 2 completion and commercialization as a medical food or 505(b)(2) drug, capitalizing on trial data for partnerships with big pharma like Novo Nordisk players in the space.[2][6] Trends like integrated CGM-insulin systems, beta-cell therapies, and immunotherapies will amplify demand for adjuvant orals improving insulin sensitivity; colon-targeted delivery may expand to NASH and obesity combos.[1][5][6] Its influence could grow via IP licensing or acquisitions, bridging nutraceuticals and pharma to democratize bariatric-like outcomes, returning to its core promise of simple, safe oral cardiometabolic fixes.[1][4]
BioKier has raised $2.0M in total across 1 funding round.
BioKier's investors include Broadview Ventures.
BioKier has raised $2.0M across 1 funding round. Most recently, it raised $2.0M Seed in July 2013.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jul 1, 2013 | $2.0M Seed | Broadview Ventures |